In addition, the increase in hepatic PD1+CXCR6+CD8+ T cells during NASH-HCC progression impairs anti-tumor immunotherapy against HCC [48]. This evidence concerns the gene CXCR6 and metabolic dysfunction-associated steatohepatitis.